AlloVir Inc.

6.66-1.95-22.65%Vol 1.62M1Y Perf -57.63%
Aug 11th, 2022 16:00 DELAYED
BID6.30 ASK6.71
Open8.52 Previous Close8.61
Pre-Market- After-Market6.70
 - -  0.04 0.60%
Target Price
32.00 
Analyst Rating
Strong Buy 1.13
Potential %
380.48 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-79/-93 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-82/-97 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-87/-94 
Income Ranking
 —    -
Price Range Ratio 52W %
15.02 
Earnings Rating
Market Cap417.38M 
Earnings Date
5th Aug 2022
Alpha-0.07 Standard Deviation0.22
Beta1.47 

Today's Price Range

6.298.52

52W Range

3.1726.41

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
-14.18%
1 Month
35.64%
3 Months
70.33%
6 Months
-23.97%
1 Year
-57.63%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALVR6.66-1.9500-22.65
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.70-0.691.43
Q01 2022-0.74-0.696.76
Q04 2021-0.71-0.92-29.58
Q03 2021-0.59-0.72-22.03
Q02 2021-0.46-0.60-30.43
Q01 2021-0.40-0.50-25.00
Q03 2020-0.33-0.58-75.76
Q02 2020-0.32-4.43-1 284.38
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.70
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume1.62M
Shares Outstanding62.67K
Shares Float10.03M
Trades Count18.52K
Dollar Volume11.15M
Avg. Volume621.58K
Avg. Weekly Volume737.08K
Avg. Monthly Volume634.43K
Avg. Quarterly Volume493.23K

AlloVir Inc. (NASDAQ: ALVR) stock closed at 6.66 per share at the end of the most recent trading day (a -22.65% change compared to the prior day closing price) with a volume of 1.62M shares and market capitalization of 417.38M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 53 people. AlloVir Inc. CEO is David Hallal.

The one-year performance of AlloVir Inc. stock is -57.63%, while year-to-date (YTD) performance is -48.53%. ALVR stock has a five-year performance of %. Its 52-week range is between 3.17 and 26.41, which gives ALVR stock a 52-week price range ratio of 15.02%

AlloVir Inc. currently has a PE ratio of -1.70, a price-to-book (PB) ratio of 1.72, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -63.50%, a ROC of -66.79% and a ROE of -70.84%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from AlloVir Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.70 for the next earnings report. AlloVir Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for AlloVir Inc. is Strong Buy (1.13), with a target price of $32, which is +380.48% compared to the current price. The earnings rating for AlloVir Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AlloVir Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AlloVir Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 19.45, ATR14 : 0.85, CCI20 : 98.46, Chaikin Money Flow : -0.14, MACD : 0.77, Money Flow Index : 72.26, ROC : 44.47, RSI : 50.03, STOCH (14,3) : 52.80, STOCH RSI : 0.24, UO : 58.79, Williams %R : -47.20), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AlloVir Inc. in the last 12-months were: Agustin Melian (Sold 26 189 shares of value $627 360 ), Ann Leen (Sold 20 988 shares of value $465 559 ), Brett R. Hagen (Sold 1 839 shares of value $15 525 ), David Hallal (Sold 91 279 shares of value $425 335 ), Diana Brainard (Sold 29 135 shares of value $126 257 ), Ercem Atillasoy (Sold 10 289 shares of value $98 448 ), Jeffrey S. Bornstein (Buy at a value of $67 547), Jeroen B. Van Beek (Sold 91 602 shares of value $1 420 849 ), Morana Jovan-Embiricos (Sold 57 576 shares of value $1 427 646 ), Vikas Sinha (Sold 18 088 shares of value $143 377 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (75.00 %)
3 (75.00 %)
3 (75.00 %)
Moderate Buy
1 (25.00 %)
1 (25.00 %)
1 (25.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.13
Strong Buy
1.13
Strong Buy
1.13

AlloVir Inc.

AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.

CEO: David Hallal

Telephone: +1 617 433-2605

Address: 139 Main Street, Cambridge 02142, MA, US

Number of employees: 53

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

59%41%

Bearish Bullish

66%34%

Bearish Bullish

71%29%

TipRanks News for ALVR

Wed, 23 Mar 2022 13:58 GMT AlloVir (ALVR) Gets a Buy Rating from Leerink Partners

- TipRanks. All rights reserved.

Tue, 18 Jan 2022 16:30 GMT Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), AlloVir (ALVR) and SI-Bone (SIBN)

- TipRanks. All rights reserved.

News

Stocktwits